Department of Psychiatry, Massachusetts General Hospital, 55 Fruit Street/Blake 11, Boston, MA, USA.
Neuropsychiatr Dis Treat. 2010 May 6;6:123-36. doi: 10.2147/ndt.s6880.
Depression and anxiety occur at high rates among patients suffering an acute coronary syndrome (ACS). Both depressive symptoms and anxiety appear to adversely affect in-hospital and long term cardiac outcomes of post-ACS patients, independent of traditional risk factors. Despite their high prevalence and serious impact, mood and anxiety symptoms go unrecognized and untreated in most ACS patients and such symptoms (rather than being transient reactions to ACS) persist for months and beyond. The mechanisms by which depression and anxiety are linked to these negative medical outcomes are likely a combination of the effects of these conditions on inflammation, catecholamines, heart rate variability, and endothelial function, along with effects on health-promoting behavior. Fortunately, standard treatments for these disorders appear to be safe, well-tolerated and efficacious in this population; indeed, selective serotonin reuptake inhibitors may actually improve cardiac outcomes. Future research goals include gaining a better understanding of the combined effects of depression and anxiety, as well as definitive prospective studies of the impact of treatment on cardiac outcomes. Clinically, protocols that allow for efficient and systematic screening, evaluation, and treatment for depression and anxiety in cardiac patients are critical to help patients avoid the devastating effects of these illnesses on quality of life and cardiac health.
抑郁和焦虑在急性冠状动脉综合征(ACS)患者中发生率较高。抑郁症状和焦虑似乎都对 ACS 后患者的住院和长期心脏预后产生不利影响,独立于传统危险因素。尽管情绪和焦虑症状在大多数 ACS 患者中普遍存在且影响严重,但这些症状并未得到识别和治疗,且这些症状(而不是对 ACS 的短暂反应)会持续数月甚至更长时间。抑郁和焦虑与这些负面医疗结果相关的机制可能是这些疾病对炎症、儿茶酚胺、心率变异性和内皮功能的影响,以及对促进健康行为的影响的综合作用。幸运的是,这些疾病的标准治疗方法在该人群中似乎是安全的、耐受良好且有效的;实际上,选择性 5-羟色胺再摄取抑制剂实际上可能改善心脏预后。未来的研究目标包括更好地了解抑郁和焦虑的综合影响,以及对治疗对心脏预后的影响进行明确的前瞻性研究。临床上,允许对心脏患者进行高效和系统的抑郁和焦虑筛查、评估和治疗的方案对于帮助患者避免这些疾病对生活质量和心脏健康产生破坏性影响至关重要。